Assertio Agrees to $125M Sale to Garda Therapeutics Amid Portfolio Shake-Up
Event summary
- Assertio Holdings to be acquired by Garda Therapeutics for $18 per share ($125.1M total) plus contingent value rights.
- Cosette Pharmaceuticals acquires non-Rolvedon assets for $35M upfront plus earnouts.
- Deal represents 34.6% premium over unaffected stock price as of March 20, 2026.
- Transaction expected to close in Q2 2026 with no regulatory approvals required.
- Assertio's common stock will delist from Nasdaq post-acquisition.
The big picture
This acquisition represents a strategic consolidation in the specialty pharmaceutical space, with Garda gaining Assertio's oncology-focused Rolvedon while shedding other assets to Cosette. The deal comes amid evolving regulatory and reimbursement landscapes, reflecting Assertio's board decision to pursue shareholder value realization through this transaction structure rather than continuing as an independent entity.
What we're watching
- Strategic Fit
- Whether Garda can successfully integrate Assertio's Rolvedon-focused portfolio into its operations.
- Contingent Value
- The likelihood of Sprix-related milestones being achieved to trigger the CVR payouts for shareholders.
- Competing Offers
- Potential emergence of superior bids during the 20-day window-shop period that could disrupt the transaction.
Related topics